MAPK4 Inhibitors: Targeting The MAPK4 Pathway for Therapeutic Benefits

Target Name: MAPK4

NCBI ID: G5596

MAPK4

MAPK4 Inhibitors: Targeting The MAPK4 Pathway for Therapeutic Benefits

MAPK4, also known as Erk3-related, is a protein that plays a crucial role in cell signaling pathways. It is a part of the MAPK4 signaling pathway, which regulates various cellular processes such as cell growth, differentiation, and response to stimuli.

MAPK4 is composed of four subunits: MAPK4A, MAPK4B, MAPK4B2, and MAPK4B3. The MAPK4A subunit is the catalytic subunit, while the MAPK4B subunit interacts with the MAPK4A subunit to regulate the signaling pathway.

The MAPK4 signaling pathway is activated by various signaling molecules, including growth factors, physical stimulation, and chemical stress. When the pathway is activated, MAPK4B2 and MAPK4B3 are recruited to the downstream target, which activates various signaling pathways, including cell proliferation, differentiation, and survival.

MAPK4 has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its role in these diseases has led to the development of MAPK4 inhibitors as potential drugs.

One of the main advantages of MAPK4 inhibitors is their ability to selectively target the MAPK4 pathway without affecting other signaling pathways. This is because MAPK4 is involved in multiple signaling pathways, including cell growth, differentiation, and stress response. By inhibiting MAPK4, researchers can target the specific pathway that is abnormal and develop more effective treatments.

MAPK4 inhibitors have been shown to be effective in various models of cancer, including breast, ovarian, and colorectal cancers. In addition, they have also been shown to be effective in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

MAPK4 inhibitors have also been shown to be effective in autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. In these diseases, MAPK4 is involved in the development of autoimmune reactions, and inhibiting MAPK4 can suppress the activity of the immune system and improve treatments.

In addition to their potential therapeutic benefits, MAPK4 inhibitors have also been shown to have potential safety benefits. Because MAPK4 is involved in multiple signaling pathways, inhibiting it is generally not toxic. In addition, MAPK4 inhibitors have also been shown to have a low risk of adverse effects, making them a potential safe drug.

In conclusion, MAPK4 is a protein that plays a crucial role in cell signaling pathways. Its role in various diseases has led to the development of MAPK4 inhibitors as potential drugs. These inhibitors have been shown to be effective in various models of cancer, neurodegenerative diseases , and autoimmune diseases. As research continues to advance, MAPK4 inhibitors are likely to become a valuable tool in the treatment of these diseases.

Protein Name: Mitogen-activated Protein Kinase 4

Functions: Atypical MAPK protein. Phosphorylates microtubule-associated protein 2 (MAP2) and MAPKAPK5. The precise role of the complex formed with MAPKAPK5 is still unclear, but the complex follows a complex set of phosphorylation events: upon interaction with atypical MAPKAPK5, ERK4/MAPK4 is phosphorylated at Ser-186 and then mediates phosphorylation and activation of MAPKAPK5, which in turn phosphorylates ERK4/MAPK4. May promote entry in the cell cycle (By similarity)

The "MAPK4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAPK4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets